JP2016507520A - 安定化されたｂ型肝炎コアポリペプチド - Google Patents

安定化されたｂ型肝炎コアポリペプチド Download PDF

Info

Publication number
JP2016507520A
JP2016507520A JP2015555242A JP2015555242A JP2016507520A JP 2016507520 A JP2016507520 A JP 2016507520A JP 2015555242 A JP2015555242 A JP 2015555242A JP 2015555242 A JP2015555242 A JP 2015555242A JP 2016507520 A JP2016507520 A JP 2016507520A
Authority
JP
Japan
Prior art keywords
hbc
amino acid
polypeptide
protein
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015555242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507520A5 (cg-RX-API-DMAC7.html
Inventor
ユーアン ルー、
ユーアン ルー、
ジェイムス ロバート スワルツ、
ジェイムス ロバート スワルツ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2016507520A publication Critical patent/JP2016507520A/ja
Publication of JP2016507520A5 publication Critical patent/JP2016507520A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32423—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015555242A 2013-01-23 2014-01-22 安定化されたｂ型肝炎コアポリペプチド Pending JP2016507520A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361755850P 2013-01-23 2013-01-23
US61/755,850 2013-01-23
US201361901243P 2013-11-07 2013-11-07
US61/901,243 2013-11-07
PCT/US2014/012586 WO2014116730A2 (en) 2013-01-23 2014-01-22 Stabilized hepatitis b core polypeptide

Publications (2)

Publication Number Publication Date
JP2016507520A true JP2016507520A (ja) 2016-03-10
JP2016507520A5 JP2016507520A5 (cg-RX-API-DMAC7.html) 2017-03-30

Family

ID=51228185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015555242A Pending JP2016507520A (ja) 2013-01-23 2014-01-22 安定化されたｂ型肝炎コアポリペプチド

Country Status (5)

Country Link
US (1) US9896483B2 (cg-RX-API-DMAC7.html)
EP (1) EP2948469A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016507520A (cg-RX-API-DMAC7.html)
CA (1) CA2936092A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014116730A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519992A (ja) * 2018-12-28 2022-03-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 操作されたｂ型肝炎コアポリペプチド

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016507520A (ja) 2013-01-23 2016-03-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 安定化されたｂ型肝炎コアポリペプチド
DE16703049T1 (de) 2015-01-15 2018-07-12 University Of Copenhagen Virusähnliche partikel mit effizienter epitopanzeige
EP3368068B1 (en) 2015-10-30 2020-11-18 University of Copenhagen Virus like particle with efficient epitope display
CN106636016B (zh) * 2017-02-24 2020-03-17 天津大学 一种通过正负电荷引入辅助病毒样颗粒自组装的方法和应用
EP3723796A1 (en) * 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
CN109666067A (zh) * 2019-01-07 2019-04-23 中国科学院过程工程研究所 一种重组病毒样颗粒及其制备方法和用途
WO2020145901A1 (en) * 2019-01-11 2020-07-16 Agency For Science, Technology And Research Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500364A (ja) * 2004-05-25 2008-01-10 キメラコア， インコーポレイテッド 自己集合性ナノ粒子薬物送達システム
WO2010042755A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008601A1 (en) 1992-10-14 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5968767A (en) 1996-06-07 1999-10-19 Genentech, Inc. Methods for in vitro protein synthesis
WO1998035062A1 (en) 1997-02-07 1998-08-13 Lingappa Jaisri R Multistep, atp-dependent cell-free system for the assembly of human immunodeficiency virus capsids
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2293489C (en) 1997-06-06 2009-09-29 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
CA2320488C (en) * 1998-02-12 2007-03-06 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
DE69929232T2 (de) 1998-10-21 2006-08-31 The United States Government As Represented By The Department Of Health And Human Services Virusähnliche partikel zur induktion von autoantikörpern
WO2000032625A1 (en) * 1998-12-04 2000-06-08 Biogen, Inc. Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
US6168931B1 (en) 1999-03-17 2001-01-02 The Board Of Trustees Of The Leland Stanford Junior University Enhanced in vitro synthesis of biological macromolecules using a novel ATP regeneration system
US6994986B2 (en) 1999-03-17 2006-02-07 The Board Of Trustees Of The Leland Stanford University In vitro synthesis of polypeptides by optimizing amino acid metabolism
US6337191B1 (en) 1999-03-22 2002-01-08 The Board Of Trustees Of The Leland Stanford Junior University Vitro protein synthesis using glycolytic intermediates as an energy source
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US6548276B2 (en) 2000-09-06 2003-04-15 The Board Of Trustees Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
US7041479B2 (en) 2000-09-06 2006-05-09 The Board Of Trustess Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
IL158418A0 (en) 2001-04-19 2004-05-12 Scripps Research Inst In vivo incorporation of unnatural amino acids
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US7615227B2 (en) 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
ES2346646T5 (es) 2002-05-30 2018-02-15 The Scripps Research Institute Ligación catalizada con cobre de azidas y acetilenos
WO2004016778A1 (en) 2002-08-19 2004-02-26 The Board Of Trustees Of The Leland Stanford Junior University Improved methods of in vitro protein synthesis
CA2497972C (en) * 2002-09-06 2016-04-26 Advanced Life Science Institute, Inc. Hbv precore protein having a particle-forming ability
EP1897548B2 (en) 2003-02-28 2024-05-22 The Johns Hopkins University T cell regulation
MXPA05009289A (es) 2003-03-26 2005-10-18 Cytos Biotechnology Ag Conjugados de particulas tipo virus del analogo del peptido melan-a.
EP1636340A4 (en) 2003-06-18 2009-02-11 Scripps Research Inst COMPLEMENTS TO THE GENETIC CODE OF UNNATURATIVE REACTIVE AMINO ACIDS
WO2005005614A2 (en) * 2003-07-03 2005-01-20 Pecos Labs, Inc. Combined b-cell and t-cell epitopes on vlp for improved vaccines
US20050054044A1 (en) 2003-07-18 2005-03-10 The Board Of Trustees Of The Leland Stanford Junior University Method of alleviating nucleotide limitations for in vitro protein synthesis
US7341852B2 (en) 2003-07-18 2008-03-11 The Board Of Trustees Of The Leland Stanford Junior University Methods of decoupling reaction scale and protein synthesis yield in batch mode
CA2541360A1 (en) 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
JP5074768B2 (ja) 2003-11-20 2012-11-14 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ インビトロにおけるタンパク質合成の改良された方法
US20050170551A1 (en) 2004-02-04 2005-08-04 Strip David R. Manufacture of flat panel light emitting devices
ES2519444T3 (es) 2004-09-21 2014-11-07 The Scripps Research Institute Incorporación in vivo de alquinil aminoácidos a proteínas en eubacterias
US9809824B2 (en) 2004-12-13 2017-11-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
AU2007348315A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating B- cell malignancies
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
US20110129438A1 (en) 2006-06-28 2011-06-02 James Robert Swartz Immunogenic protein constructs
WO2008066583A2 (en) 2006-06-29 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Cell-free synthesis of proteins containing unnatural amino acids
US20090317861A1 (en) 2006-06-29 2009-12-24 Bundy Bradley C Cell-free synthesis of virus like particles
CN101511856B (zh) 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
AU2008205479A1 (en) 2007-01-18 2008-07-24 The Board Of Trustees Of The Leland Stanford Junior University Enhanced cell-free synthesis of active proteins containing disulfide bonds
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US8445706B2 (en) 2008-09-05 2013-05-21 Board Of Trustees Of Northern Illinois University Unnatural amino acids capable of covalently modifying protein phosphatases and their use as general and specific inhibitors and probes
US20100168402A1 (en) 2008-11-14 2010-07-01 Bundy Bradley C Direct Attachment of Polypeptides to Virus Like Particles
US8324149B2 (en) 2008-11-18 2012-12-04 The Board Of Trustees Of The Leland Stanford Junior University Encapsidation of heterologous entities into virus-like particles
CA2816401C (en) 2009-11-05 2017-07-18 Novici Biotech Llc Generation of antigenic virus-like particles through protein-protein linkages
WO2011109422A2 (en) 2010-03-02 2011-09-09 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of cancer
AU2012305714A1 (en) * 2011-09-09 2014-03-27 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
EP3520809B1 (en) 2012-02-03 2025-08-06 Emory University Immunostimulatory compositions.
JP2016507520A (ja) 2013-01-23 2016-03-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 安定化されたｂ型肝炎コアポリペプチド
JP2016515538A (ja) 2013-03-15 2016-05-30 ブレット バイオテクノロジー、 インク．Ｂｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 特異的な多価ウイルス様粒子ワクチンおよびその使用
JP2017500313A (ja) 2013-12-09 2017-01-05 ブレット バイオテクノロジー， インコーポレーテッドＢｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 特異的ウイルス様粒子−ＣｐＧオリゴヌクレオチドワクチンおよびその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500364A (ja) * 2004-05-25 2008-01-10 キメラコア， インコーポレイテッド 自己集合性ナノ粒子薬物送達システム
WO2010042755A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519992A (ja) * 2018-12-28 2022-03-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 操作されたｂ型肝炎コアポリペプチド
JP7491932B2 (ja) 2018-12-28 2024-05-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 操作されたｂ型肝炎コアポリペプチド

Also Published As

Publication number Publication date
WO2014116730A3 (en) 2014-10-23
US20150329598A1 (en) 2015-11-19
US9896483B2 (en) 2018-02-20
EP2948469A4 (en) 2016-11-02
EP2948469A2 (en) 2015-12-02
WO2014116730A2 (en) 2014-07-31
CA2936092A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
JP2016507520A (ja) 安定化されたｂ型肝炎コアポリペプチド
Patel et al. Surface functionalization of virus-like particles by direct conjugation using azide− alkyne click chemistry
Bundy et al. Escherichia coli‐based cell‐free synthesis of virus‐like particles
JP5620100B2 (ja) 非天然アミノ酸を含有するタンパク質の無細胞合成の方法
US20090317861A1 (en) Cell-free synthesis of virus like particles
CA3094859A1 (en) Proteolipid vesicles formulated with fusion associated small transmembrane proteins
CN113564214A (zh) 蛋白质体外合成纯化一体化制备方法、试剂盒及其应用
JP7646778B2 (ja) 改変型ｐｉｇｇｙＢａｃトランスポゼースのポリペプチド、それをコードするポリヌクレオチド、導入キャリア、キット、細胞のゲノムに目的配列を組込む方法及び細胞製造方法
US8324149B2 (en) Encapsidation of heterologous entities into virus-like particles
US20100168402A1 (en) Direct Attachment of Polypeptides to Virus Like Particles
US9550813B2 (en) Disulfide stabilized foldon polypeptides
JPWO2018074558A1 (ja) 複合ポリペプチド単量体、細胞浸透機能を有する当該複合ポリペプチドの単量体の会合体、及び、当該会合体を有効成分とする皮下、皮内、経皮又は筋肉内投与用ノロウイルスコンポーネントワクチン
US9255255B2 (en) Synthesis of linear and branched polymers of polypeptides through direct conjugation
US20240091343A1 (en) Technology platform of uncapped-linear mrna with unmodified uridine
US20060141042A1 (en) Hollow nanoparticle having modified cysteine residue and drug with the use thereof
US20220281924A1 (en) Engineered hepatitis b core polypeptide
US9296792B2 (en) Ordered flagellin array as an immunostimulant
JP7609793B2 (ja) バイオコンジュゲーションのために操作されたｃｄ４７の細胞外ドメイン
CN120248078B (zh) 一种基于arc蛋白的修饰多肽及其作为核酸递送载体的应用
Brown Bacteriophage Qβ: a versatile platform for Nanoengineering
Fogarty Development of a Modular Virus-like Particle Vaccine Platform

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180703